Le Lézard
Classified in: Health, Science and technology, Business
Subject: CON

Montana-Based xD Bio Inc. Receives STTR Grant for Genomic Work


WHITEFISH, Mont., Nov. 19, 2019 /PRNewswire/ -- xD Bio Inc., a privately held, Montana-based company announced today that the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), has awarded the company $149,959 over 6 months for the first phase of a Small Business Technology Transfer (STTR) grant. The award supports researchers at xD Bio and collaborators at the Encyclopedia of DNA Elements (ENCODE) Data Coordinating Center (DCC) at Stanford University to demonstrate the ability to run advanced computational analyses developed by the ENCODE DCC directly through a web interface on xD Bio's web based platform, Truwl.com.

Truwl is xD Bio's flagship product that enables researchers to find, understand, use, and share computational methods for DNA sequencing data on a publicly available web-based platform. As generating large sequencing datasets becomes ubiquitous in biomedical fields, researchers depend ever more heavily on finding and implementing computational methods to make sense of the data. Making a user-friendly and centralized site for researchers to explore and collaborate on methods will remove significant barriers in the data analysis process. The development of the web interface and connected cloud compute infrastructure supported by this award is a first step to allow researchers to run analyses directly from Truwl without having to configure their own compute environments. Focusing on the thoroughly vetted, high impact methods developed by the ENCODE DCC will provide maximum value to the genomics research community.

Research reported in this publication was supported by the National Human Genome Research Institute of the National Institutes of Health under Award Number R41HG010844. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

For further information contact:
Karl Sebby, Ph.D.
[email protected]
406-219-8345

 

SOURCE xD Bio Inc.


These press releases may also interest you

at 05:11
Hyundai Bioscience announced on April 25th that its clinical development plan of oral "Niclosamide Metabolic Anticancer Drug" targeting cancer patients with intractable cancer caused by p53 gene mutations. Mutations in the p53 gene occur in almost...

at 04:31
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CHINA, HONG KONG, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR...

at 04:30
The Balance RehabClinic, renowned for its luxury mental health and addiction services, proudly announces its expansion into The Balance Healthcare Group: a collection of premium mental health solutions tailored for affluent individuals. These new...

at 03:47
Zest Dental Solutions, a global leader in innovative dental solutions proudly announces a strategic partnership with The Pathway. Founded by Justin Moody, DDS and based in Arizona, The Pathway is a continuing education program that teaches dentists...

at 03:34
Medivir AB (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that its selective cathepsin K inhibitor, MIV-711, has been granted Rare Pediatric Disease...

at 03:16
First quarter Net sales reached SEK 9.4 (13.0) million.The operating result totaled SEK -18.4 (-14.4) million.Earnings per share, basic and diluted, were SEK -0.11 (-0.09).Cash flow from operating activities totaled SEK -7.3 (-12.2) million.CEO...



News published on and distributed by: